cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25402/nnm.25211414
title: Tannin-albumin particles as stable carriers of medicines - supplementary material

description: Supplementary figures 1-4 Table S1. Results of molecular docking (Vina Score) of Punicalin and Punicalagin with Drug site 1 by different crystallographic structuresTable S2. Results of molecular docking (Vina Score) of Punicalin and Punicalagin with Drug site 2 by different crystallographic structures.Table S3. Results of molecular docking (Vina Score) of Punicalin and Punicalagin with Drug site 3 by different crystallographic structures.Table S4. Results of molecular docking (Vina Score) of Punicalin and Punicalagin with Drug site 4 by different crystallographic structures.Table S5. Results of molecular docking (Vina Score) of Punicalin and Punicalagin with Drug site 5 by different crystallographic structures.
DOI: 10.25402/nnm.25211414.v1
title: Tannin-albumin particles as stable carriers of medicines - supplementary material

description: Supplementary figures 1-4 Table S1. Results of molecular docking (Vina Score) of Punicalin and Punicalagin with Drug site 1 by different crystallographic structuresTable S2. Results of molecular docking (Vina Score) of Punicalin and Punicalagin with Drug site 2 by different crystallographic structures.Table S3. Results of molecular docking (Vina Score) of Punicalin and Punicalagin with Drug site 3 by different crystallographic structures.Table S4. Results of molecular docking (Vina Score) of Punicalin and Punicalagin with Drug site 4 by different crystallographic structures.Table S5. Results of molecular docking (Vina Score) of Punicalin and Punicalagin with Drug site 5 by different crystallographic structures.
DOI: 10.25402/nnm.25272658
title: Cross-protection induced by virus-like particles containing influenza dual-hemagglutinin and M2 ectodomain - supplementary material

description: Supplementary Table 1. Homology of hemagglutinin between influenza A/Guangdong-Maonan/SWL1536/2019 (H1N1) virus and antigenically different strainsSupplementary Table 2. Homology of hemagglutinin between influenza A/Hong Kong/ 2671/2019 (H3N2) virus and antigenically different strains
DOI: 10.25549/examiner-c44-17363
title: Swan story, 1951

description: 8 images. Swan story, 30 August 1951. Mrs. Joan White; Mrs. Mina Struebing; Mrs. Diane Isaacs; Mrs. Lucille C. Burckhalter.
DOI: 10.25402/nnm.25272658.v1
title: Cross-protection induced by virus-like particles containing influenza dual-hemagglutinin and M2 ectodomain - supplementary material

description: Supplementary Table 1. Homology of hemagglutinin between influenza A/Guangdong-Maonan/SWL1536/2019 (H1N1) virus and antigenically different strainsSupplementary Table 2. Homology of hemagglutinin between influenza A/Hong Kong/ 2671/2019 (H3N2) virus and antigenically different strains
DOI: 10.25402/nnm.25324645
title: Biocompatible carbon quantum dots as versatile imaging nanotrackers of fungal pathogen –<i> Candida albicans</i>

description: <b>Aim: </b>The development of carbon quantum dots (C-QDs) as nanotrackers to understand drug–pathogen interactions, virulence and multidrug resistance. <b>Methods: </b>Microwave synthesis of C-QDs was performed using citric acid and polyethylene glycol. Further, <i>in vitro </i>toxicity was evaluated and imaging applications were demonstrated in <i>Candida albicans </i>isolates. <b>Results: </b>Well-dispersed, ultra small C-QDs exhibited no cyto<b>/</b>microbial<b>/</b>reactive oxygen species-mediated toxicity and internalized effectively in <i>Candida </i>yeast and hyphal cells. C-QDs were employed for confocal imaging of drug-sensitive and -resistant cells, and a study of the yeast-to-hyphal transition using atomic force microscopy in <i>Candida </i>was conducted for the first time. <b>Conclusion: </b>These biocompatible C-QDs have promising potential as next-generation nanotrackers for <i>in vitro </i>and <i>in vivo </i>targeted cellular and live imaging, after functionalization with biomolecules and drugs.<b>Plain language summary: </b>Scientists have used radiolabeled drugs and radioactive tracking agents for the imaging and study of drug resistance in microbial pathogens. But, these radiolabeled drugs or radiotrackers pose health hazards and environmental risks. However, such limitations can be overcome by designing nontoxic, environment-friendly, nanotechnology-based fluorescent imaging agents. This study demonstrates the development and application of cost-effective, nontoxic carbon-based quantum dots for imaging of drug-sensitive and -resistant microbial strains and transition to different morphological forms (yeast-to-hyphae transition) in fungal pathogens. The results demonstrated the suitability of carbon quantum dots as next-generation nano-based bioimaging<b>/</b>tracking agents for cellular imaging. The availability of such nontoxic fluorescent tracking agents is likely to offer promising solutions in therapeutics and diagnostics by providing insight into various mechanisms and functional links related to drug resistance, virulence and pathogenicity.
DOI: 10.25402/nnm.25324645.v1
title: Biocompatible carbon quantum dots as versatile imaging nanotrackers of fungal pathogen –<i> Candida albicans</i>

description: <b>Aim: </b>The development of carbon quantum dots (C-QDs) as nanotrackers to understand drug–pathogen interactions, virulence and multidrug resistance. <b>Methods: </b>Microwave synthesis of C-QDs was performed using citric acid and polyethylene glycol. Further, <i>in vitro </i>toxicity was evaluated and imaging applications were demonstrated in <i>Candida albicans </i>isolates. <b>Results: </b>Well-dispersed, ultra small C-QDs exhibited no cyto<b>/</b>microbial<b>/</b>reactive oxygen species-mediated toxicity and internalized effectively in <i>Candida </i>yeast and hyphal cells. C-QDs were employed for confocal imaging of drug-sensitive and -resistant cells, and a study of the yeast-to-hyphal transition using atomic force microscopy in <i>Candida </i>was conducted for the first time. <b>Conclusion: </b>These biocompatible C-QDs have promising potential as next-generation nanotrackers for <i>in vitro </i>and <i>in vivo </i>targeted cellular and live imaging, after functionalization with biomolecules and drugs.<b>Plain language summary: </b>Scientists have used radiolabeled drugs and radioactive tracking agents for the imaging and study of drug resistance in microbial pathogens. But, these radiolabeled drugs or radiotrackers pose health hazards and environmental risks. However, such limitations can be overcome by designing nontoxic, environment-friendly, nanotechnology-based fluorescent imaging agents. This study demonstrates the development and application of cost-effective, nontoxic carbon-based quantum dots for imaging of drug-sensitive and -resistant microbial strains and transition to different morphological forms (yeast-to-hyphae transition) in fungal pathogens. The results demonstrated the suitability of carbon quantum dots as next-generation nano-based bioimaging<b>/</b>tracking agents for cellular imaging. The availability of such nontoxic fluorescent tracking agents is likely to offer promising solutions in therapeutics and diagnostics by providing insight into various mechanisms and functional links related to drug resistance, virulence and pathogenicity.
DOI: 10.25549/examiner-c44-73394
title: Name made legal, 1959

description: 3 images. Name made legal, 9 October 1959. Tuesday Weld (actress).; Caption slip reads: "Photographer: Tompkins. Date: 1959-10-09. Reporter: Tompkins. Assignment: Actress Tuesday Weld in Santa Monica Superior court for name change. 1d, 2d, 40d - Actress Tuesday Weld has name made legal in Santa Monica Superior Court".
DOI: 10.25402/nnm.25324669
title: Neutrophil and endothelial cell membranes coassembled roflumilast nanoparticles attenuate myocardial ischemia/reperfusion injury

description: <b>Aim: </b>This study aimed to develop biomimetic nanoparticles (NPs) of roflumilast (ROF) for attenuating myocardial ischemia/reperfusion (MI/R) injury. <b>Materials & methods: </b>We synthesized biomimetic ROF NPs and assembled ROF NPs in neutrophil and endothelial cell membranes (NE/ROF NPs). The physical properties of NE/ROF NPs were characterized and biological functions of NE/ROF NPs were tested <i>in vitro</i>. Targeting characteristics, therapeutic efficacy and safety of NE/ROF NPs were examined in mice model of MI/R. <b>Results: </b>NE/ROF NPs exhibited significant anti-inflammatory and antiadhesion effects. Meanwhile, they was effective in reducingMI/R injury in mice. Furthermore, NE/ROF NPs exhibited stronger targeting capabilities and demonstrated good safety. <b>Conclusion: </b>NE/ROF NPs may be a versatile biomimetic drugdelivery system for attenuating MI/R injury.
DOI: 10.25402/nnm.25324669.v1
title: Neutrophil and endothelial cell membranes coassembled roflumilast nanoparticles attenuate myocardial ischemia/reperfusion injury

description: <b>Aim: </b>This study aimed to develop biomimetic nanoparticles (NPs) of roflumilast (ROF) for attenuating myocardial ischemia/reperfusion (MI/R) injury. <b>Materials & methods: </b>We synthesized biomimetic ROF NPs and assembled ROF NPs in neutrophil and endothelial cell membranes (NE/ROF NPs). The physical properties of NE/ROF NPs were characterized and biological functions of NE/ROF NPs were tested <i>in vitro</i>. Targeting characteristics, therapeutic efficacy and safety of NE/ROF NPs were examined in mice model of MI/R. <b>Results: </b>NE/ROF NPs exhibited significant anti-inflammatory and antiadhesion effects. Meanwhile, they was effective in reducingMI/R injury in mice. Furthermore, NE/ROF NPs exhibited stronger targeting capabilities and demonstrated good safety. <b>Conclusion: </b>NE/ROF NPs may be a versatile biomimetic drugdelivery system for attenuating MI/R injury.
DOI: 10.25549/examiner-c44-73255
title: Rim-of-the-World fire (Lake Arrowhead), 1953

description: 12 images. Rim-of-the-World fire (Lake Arrowhead), 27 August 1953. Vernet Poupitch (moves furniture from his house); Deputy Sheriff Duane Mellinger; Dave Leamon (Lake Arrowhead Forest Service).; Caption slip reads: "Photographer: Paegel. Date: 1953-08-27. Reporter: Harmon. Assignment: Arrowhead Fire. 15-16-17-18: Views looking East of Arrowhead Highlands -- Crest Forest Fire Equipment in foreground standing by".; Additional caption slip reads: "Photographer: Forbes. Date: 1953-08-27. Assignment: Fire. 1: Flames jump Rim of World Road. 146: Indians from Arizona rest & eat. 145-138: Cutting tree with power saw. 27: Vernet Poupitch moves furniture from his place at Rim Forest. 137: Dep Sher Duane Mellinger tells people to move. 135-136-304: Dave Leamon, Lake Arrowhead Forestry Service off Blue Jay Daily Canyon. 137: Dep Sher Duane Mellinger telling people to move".
DOI: 10.25402/nnm.25342828
title: Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma<i> in situ</i>

description: <b>Aims: </b>This study was aimed to formulate erlotinib (ERL)-loaded transferosomal gel (ERL@TG) intended for topical application for the treatment of ductal carcinoma <i>in situ</i>. <b>Materials & methods: </b>The optimized process involved a thin-film hydration method to generate ERL-loaded transferosomes (ERL@TFS), which was incorporated into a carbopol gel matrix to generate ERL@TG. The optimized formulation was characterized <i>in vitro </i>followed by cytotoxicity evaluation on MCF-7 breast cancer cell lines and acute toxicity and skin irritation studies was performed <i>in vivo</i>. <b>Results: </b>In a comparative assessment against plain ERL, ERL@TG displayed enhanced efficacy against MCF-7 cell lines, reflected in considerably lower IC50 values with an enhanced safety profile. <b>Conclusion: </b>Optimized ERL@TG was identified as a promising avenue for addressing ductal carcinoma <i>in situ </i>breast cancer.<b>Plain language summary: </b>Despite progress, breast cancer remains a significant cause of death. This study aimed to revolutionize the treatment of noninvasive ductal carcinoma <i>in situ</i>, a type of breast cancer, by developing a special gel that can be applied directly to the breast. The developed gel was in the nanoform, a ‘nanotransfersomal’ gel that contained erlotinib, a potent drug for breast cancer. To ensure its effectiveness, we evaluated the erlotinib-loaded transfersomal gel through various tests. The results confirmed that the gel was nano-sized and loaded with a high amount of erlotinib. Animal studies were conducted to check if the prepared gel caused any skin irritation and interestingly, there was no irritation observed on the animals’ skin. Furthermore, we treated breast cancer cells with the developed gel using a method called MTT assay and the results showed improved cell-killing activity in comparison to plain drug. In conclusion, this special gel represents a breakthrough in breast cancer treatment. It offers hope for better outcomes in the fight against this disease. This innovative approach involves directly applying the gel on the affected area topically to increase patient compliance and decreasing side effects of drugs. This could potentially transform ductal carcinoma <i>in situ </i>breast cancer treatment, bringing us closer to improved treatments and outcomes.
DOI: 10.25402/nnm.25342828.v1
title: Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma<i> in situ</i>

description: <b>Aims: </b>This study was aimed to formulate erlotinib (ERL)-loaded transferosomal gel (ERL@TG) intended for topical application for the treatment of ductal carcinoma <i>in situ</i>. <b>Materials & methods: </b>The optimized process involved a thin-film hydration method to generate ERL-loaded transferosomes (ERL@TFS), which was incorporated into a carbopol gel matrix to generate ERL@TG. The optimized formulation was characterized <i>in vitro </i>followed by cytotoxicity evaluation on MCF-7 breast cancer cell lines and acute toxicity and skin irritation studies was performed <i>in vivo</i>. <b>Results: </b>In a comparative assessment against plain ERL, ERL@TG displayed enhanced efficacy against MCF-7 cell lines, reflected in considerably lower IC50 values with an enhanced safety profile. <b>Conclusion: </b>Optimized ERL@TG was identified as a promising avenue for addressing ductal carcinoma <i>in situ </i>breast cancer.<b>Plain language summary: </b>Despite progress, breast cancer remains a significant cause of death. This study aimed to revolutionize the treatment of noninvasive ductal carcinoma <i>in situ</i>, a type of breast cancer, by developing a special gel that can be applied directly to the breast. The developed gel was in the nanoform, a ‘nanotransfersomal’ gel that contained erlotinib, a potent drug for breast cancer. To ensure its effectiveness, we evaluated the erlotinib-loaded transfersomal gel through various tests. The results confirmed that the gel was nano-sized and loaded with a high amount of erlotinib. Animal studies were conducted to check if the prepared gel caused any skin irritation and interestingly, there was no irritation observed on the animals’ skin. Furthermore, we treated breast cancer cells with the developed gel using a method called MTT assay and the results showed improved cell-killing activity in comparison to plain drug. In conclusion, this special gel represents a breakthrough in breast cancer treatment. It offers hope for better outcomes in the fight against this disease. This innovative approach involves directly applying the gel on the affected area topically to increase patient compliance and decreasing side effects of drugs. This could potentially transform ductal carcinoma <i>in situ </i>breast cancer treatment, bringing us closer to improved treatments and outcomes.
DOI: 10.25549/examiner-c44-52491
title: Scouts Hawaii trip, 1958

description: 2 images. Scouts Hawaii trip, 27 June 1958. Troop twelve of Burbank demonstrate how they earned their money for two week vacation to Hawaii.; Caption slip reads: "Photographer: Glickman. Date: 1958-06-27. Assignment: Boy scouts trip to Hawaii. 111/112: Members of boy scout troop #12 of Burbank demonstrate how they earned their extra money for two week Hawaiian vacation".
DOI: 10.25402/nnm.25348447
title: Biopolymer-based tumor microenvironment-responsive nanomedicine for targeted cancer therapy

description: Nanomedicine has opened up new avenues for cancer treatment by enhancing drug solubility, permeability and targeted delivery to cancer cells. Despite its numerous advantages over conventional therapies, nanomedicine may exhibit off-target drug distribution, harming nontarget regions. The increased permeation and retention effect of nanomedicine in tumor sites also has its limitations, as abnormal tumor vasculature, dense stroma structure and altered tumor microenvironment (TME) may result in limited intratumor distribution and therapeutic failure. However, TME-responsive nanomedicine has exhibited immense potential for efficient, safe and precise delivery of therapeutics utilizing stimuli specific to the TME. This review discusses the mechanistic aspects of various TME-responsive biopolymers and their application in developing various types of TME-responsive nanomedicine.
DOI: 10.25402/nnm.25348447.v1
title: Biopolymer-based tumor microenvironment-responsive nanomedicine for targeted cancer therapy

description: Nanomedicine has opened up new avenues for cancer treatment by enhancing drug solubility, permeability and targeted delivery to cancer cells. Despite its numerous advantages over conventional therapies, nanomedicine may exhibit off-target drug distribution, harming nontarget regions. The increased permeation and retention effect of nanomedicine in tumor sites also has its limitations, as abnormal tumor vasculature, dense stroma structure and altered tumor microenvironment (TME) may result in limited intratumor distribution and therapeutic failure. However, TME-responsive nanomedicine has exhibited immense potential for efficient, safe and precise delivery of therapeutics utilizing stimuli specific to the TME. This review discusses the mechanistic aspects of various TME-responsive biopolymers and their application in developing various types of TME-responsive nanomedicine.
DOI: 10.25402/nnm.25348468
title: Advances in nanomedicines: a promising therapeutic strategy for ischemic cerebral stroke treatment

description: Ischemic stroke, prevalent among the elderly, necessitates attention to reperfusion injury post treatment. Limited drug access to the brain, owing to the blood–brain barrier, restricts clinical applications. Identifying efficient drug carriers capable of penetrating this barrier is crucial. Blood–brain barrier transporters play a vital role in nutrient transport to the brain. Recently, nanoparticles emerged as drug carriers, enhancing drug permeability via surface-modified ligands. This article introduces the blood–brain barrier structure, elucidates reperfusion injury pathogenesis, compiles ischemic stroke treatment drugs, explores nanomaterials for drug encapsulation and emphasizes their advantages over conventional drugs. Utilizing nanoparticles as drug-delivery systems offers targeting and efficiency benefits absent in traditional drugs. The prospects for nanomedicine in stroke treatment are promising.
DOI: 10.25549/examiner-c44-52298
title: Boxing, 1958

description: 18 images. Boxing, 25 July 1958. Pete Radamacher; Zora Folley; Caption slip reads: "Photographer: Rustan. Date: 1958-07-25. Assignment: Fights - Rademacher; Folley. Special Instructions: Deb 7 or 8 min. 23/23//99/100: 1st Round. 48: 2nd round. 47/50: 3rd Round. 4th Round".; Caption slip reads: "Photographer: Jensen. J9: 1st Round".
DOI: 10.25402/nnm.25348468.v1
title: Advances in nanomedicines: a promising therapeutic strategy for ischemic cerebral stroke treatment

description: Ischemic stroke, prevalent among the elderly, necessitates attention to reperfusion injury post treatment. Limited drug access to the brain, owing to the blood–brain barrier, restricts clinical applications. Identifying efficient drug carriers capable of penetrating this barrier is crucial. Blood–brain barrier transporters play a vital role in nutrient transport to the brain. Recently, nanoparticles emerged as drug carriers, enhancing drug permeability via surface-modified ligands. This article introduces the blood–brain barrier structure, elucidates reperfusion injury pathogenesis, compiles ischemic stroke treatment drugs, explores nanomaterials for drug encapsulation and emphasizes their advantages over conventional drugs. Utilizing nanoparticles as drug-delivery systems offers targeting and efficiency benefits absent in traditional drugs. The prospects for nanomedicine in stroke treatment are promising.
DOI: 10.25402/nnm.25407820
title: Revamping the corneal permeability and antiglaucoma therapeutic potential of brinzolamide using transniosomes: optimization, in vitro and preclinical evaluation

description: <b>Aim: </b>This study aims to explore potential of transniosomes, a hybrid vesicular system, as ocular drug-delivery vehicle. <b>Materials & methods: </b>Thin-film hydration technique was used to fabricate brinzolamide-loaded transniosomes (BRZ-TN) and optimized using Box–Behnken design, further exhaustively characterized for physicochemical evaluations, deformability, drug release, permeation and preclinical evaluations for antiglaucoma activity. <b>Results: </b>The BRZ-TN showed ultradeformability (deformability index: 5.71), exhibiting sustained drug release without irritation (irritancy score: 0) and high permeability compared with the marketed formulation or free drug suspension. The extensive <i>in vivo </i>investigations affirmed effective targeted delivery of transniosomes, with brinzolamide reducing intraocular pressure potentially. <b>Conclusion: </b>Our findings anticipated that BRZ-TN is a promising therapeutic nanocarrier for effectively delivering cargo to targeted sites by crossing corneal barriers.
DOI: 10.25402/nnm.25407820.v1
title: Revamping the corneal permeability and antiglaucoma therapeutic potential of brinzolamide using transniosomes: optimization, in vitro and preclinical evaluation

description: <b>Aim: </b>This study aims to explore potential of transniosomes, a hybrid vesicular system, as ocular drug-delivery vehicle. <b>Materials & methods: </b>Thin-film hydration technique was used to fabricate brinzolamide-loaded transniosomes (BRZ-TN) and optimized using Box–Behnken design, further exhaustively characterized for physicochemical evaluations, deformability, drug release, permeation and preclinical evaluations for antiglaucoma activity. <b>Results: </b>The BRZ-TN showed ultradeformability (deformability index: 5.71), exhibiting sustained drug release without irritation (irritancy score: 0) and high permeability compared with the marketed formulation or free drug suspension. The extensive <i>in vivo </i>investigations affirmed effective targeted delivery of transniosomes, with brinzolamide reducing intraocular pressure potentially. <b>Conclusion: </b>Our findings anticipated that BRZ-TN is a promising therapeutic nanocarrier for effectively delivering cargo to targeted sites by crossing corneal barriers.